TransCode Therapeutics received a deficiency letter from Nasdaq on May 19, 2026. The company failed to meet the minimum stockholders' equity requirement of $2,500,000 under Nasdaq Listing Rule 5550(b)(1). The company's Form 10-Q for the period ended March 31, 2026, reported stockholders' equity of $1,251,427. The company has until July 3, 2026, to submit a plan to regain compliance.